pd 98059 has been researched along with Dermatitis Medicamentosa in 1 studies
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one: inhibits MAP kinase kinase (MEK) activity, p42 MAPK and p44 MAPK; structure in first source
2-(2-amino-3-methoxyphenyl)chromen-4-one : A member of the class of monomethoxyflavones that is 3'-methoxyflavone bearing an additional amino substituent at position 2'.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sorafenib may cause diverse cutaneous adverse reactions, including hand-foot reaction, facial and scalp eruptions, alopecia and pruritus." | 1.46 | Sorafenib stimulates human skin type mast cell degranulation and maturation. ( Kira, Y; Mizukami, Y; Sugawara, K; Tsuruta, D, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mizukami, Y | 1 |
| Sugawara, K | 1 |
| Kira, Y | 1 |
| Tsuruta, D | 1 |
1 other study available for pd 98059 and Dermatitis Medicamentosa
| Article | Year |
|---|---|
Sorafenib stimulates human skin type mast cell degranulation and maturation.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents; Apoptosis; Biopsy; Cell Count | 2017 |